Action

Investors Target MGP Ingredients in Class Action Lawsuit Over Alleged Securities Fraud

by

NEW YORK CITY, New York — Bronstein, Gewirtz & Grossman, LLC, a prominent national law firm known for its aggressive representation in securities fraud and shareholder litigation, has announced the filing of a class action lawsuit against MGP Ingredients, Inc. and several of its top executives. The lawsuit pertains to alleged violations of federal securities laws and aims to recover damages for all entities and individuals who acquired securities in MGP Ingredients from May 4, 2023, to October 30, 2024. According to the legal complaint, MGP Ingredients and its officers are accused of providing the … Read more

FLNC Investors Called to Spearhead Key Class Action Lawsuit Against Fluence Energy, Inc. Over Alleged Securities Fraud

by

Austin, Texas – Investors who purchased shares in Fluence Energy, Inc. are now presented with the chance to lead a class action lawsuit against the firm. This opportunity arises amidst allegations that the company engaged in securities fraud which reportedly misled shareholders about its financial status and operational capabilities. The class action suit targets periods between October 28, 2021, and May 5, 2022. It claims that Fluence Energy, an energy storage technology and services company, provided false and misleading statements regarding its business operations and compliance policies. These alleged misrepresentations are said to have impacted … Read more

Switzerland’s Sandoz Takes Legal Action Against Amgen, Alleging Antitrust Violations in the US

by

Basel, Switzerland – Sandoz, a division of Swiss pharmaceutical giant Novartis AG, has launched an antitrust lawsuit against Amgen Inc. in the United States, accusing the American biotechnology firm of engaging in anti-competitive practices. The legal action, filed in the U.S. District Court for the Eastern District of Pennsylvania, alleges that Amgen has been blocking biosimilar competition to its white blood cell-boosting drugs, Neulasta and Neupogen, thus monopolizing the market. Sandoz argues that Amgen has set up a series of obstacles – ranging from questionable patents to exclusionary contracts with healthcare providers – effectively stifling … Read more

Investors Alert: Class Action Lawsuit Against SoundHound AI Targets Alleged Financial Misconduct; Deadline Approaching

by

Radnor, Pa. – A class action lawsuit was initiated against SoundHound AI, Inc., a notable Nasdaq-listed company, alleging false and misleading financial information to its investors. Kessler Topaz Meltzer & Check, LLP, the law firm handling the lawsuit, asserts that the accusations pertain to the period between May 10, 2024, and March 3, 2025. During this timeframe, it’s claimed that SoundHound mismanaged its internal controls regarding financial reporting and overstated its remediation capabilities. This has reportedly led to an inflated valuation of goodwill for its recent acquisition and may have jeopardized its ability to timely … Read more